Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.88 USD
+0.89 (1.78%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Praxis Precision Medicines, Inc. (PRAX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$140.38 | $270.00 | $40.00 | 180.82% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Praxis Precision Medicines, Inc. comes to $140.38. The forecasts range from a low of $40.00 to a high of $270.00. The average price target represents an increase of 180.82% from the last closing price of $49.99.
Analyst Price Targets (8 )
Broker Rating
Praxis Precision Medicines, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 5 |
Buy | 1 | 1 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.29 | 1.29 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/24/2024 | Needham & Company | Ami Fadia | Not Available | Moderate Buy |
6/18/2024 | Guggenheim Securities | Yatin Suneja | Not Available | Strong Buy |
6/17/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
5/16/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
5/13/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
5/1/2024 | Robert W. Baird & Co. | Joel L Beatty | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 9 |
Average Target Price | $140.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -2.39 |